269 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Mar 24
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
4:10pm
compensation expense. Research and development expenses for the quarter totaled $6.7 million, and general and administrative expenses for the quarter … 31,
Grant revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Interest income
8-K
EX-99.1
tj0f6gbes00yl6koe
9 Nov 23
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
4:15pm
8-K
EX-99.1
r8swaiort9nrg82d
10 Aug 23
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
sfk57p9 qsksz
4 May 23
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
rlv4uozaa7uxci9vyasd
3 Nov 22
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
4:17pm
8-K
EX-99.1
k1j5cjb4f3
5 May 22
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
12:00am